Patent focus on agents for osteoporosis: September 1999 - February 2000

Abstract

This patent focus discusses the most interesting disclosures in the field of osteoporosis during the specified six month period. Many of the patents highlighted are relevant to the oestrogen receptor: either new chemical agents with possible use as selective oestrogen receptor modulators (SERMs) or new therapeutic combination options. Also discussed are other antiresorptive approaches, such as α_vβ₃ integrin antagonists, Src kinase inhibitors and cathepsin inhibitors. Furthermore, patents regarding vitamin D analogues and disclosures describing bone anabolic approaches, such as prostaglandin analogues and calcilytics, are discussed. No disclosures relating to bisphosphonates appeared during this time.

• alphavbeta3 integrin
• bone morphogenetic protein
• calcilytics
• cathepsin K
• oestrogen receptor
• osteoporosis
• prostaglandin
• SERM
• Src kinase
• vitamin D